journal article·2018-08

Combinational drug delivery using nanocarriers for breast cancer treatments: A review

Nafise Olov, Shadab Bagheri‐Khoulenjani, Hamid Mirzadeh

Publisher page

Abstract

Abstract Breast cancer (BC) is the most common cancer in women that requires special attention due to low response to conventional treatments. The common method for treating cancer (especially BC) is applying a single anticancer agent, however, due to some disadvantages including cytotoxicity, side effects, and multidrug resistance, the efficiency and application of this method are limited. To overcome these challenges, the combinational delivery of anticancer drugs (including chemical agents, genetic materials, etc.) has been introduced. To increase the efficacy of this new method, several nanocarriers including inorganic nanoparticles (such as, magnetic nanoparticles, silica nanoparticles, etc.) and organic ones (e.g., dendrimers, liposomes, micelles, and polymeric nanoparticles) have been used. Based on the literature, combinational delivery using nanocarriers showed promising results in the treatment of BC. In this review, combination regimens for the treatment of BC, nanocarriers containing combinations of pharmaceutical agents (including small molecule chemotherapeutic, biological, and gene therapy agents) as an opportunity to overcome chemotherapy challenges and, finally, examples of these formulations have been presented. This review aims to provide a better understanding of these increasingly important new methods of cancer treatment and the main issues and key considerations for a rational design of nanocarriers used in combinational delivery of different synergistic anticancer agents. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 2272‐2283, 2018.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Polymer and Color Engineering Department Amirkabir University of Technology, 424 Hafez‐Avenue 15875‐4413 Tehran Iran

References (96)

Show source-provided references
1. American Cancer Society. How Common Is Breast Cancer? [Internet]. American Cancer Society;2017. Available from:https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html#references
2. 10.1016/j.jconrel.2016.06.01210.1016/j.jconrel.2016.06.012 ↗
3. 10.1016/j.coph.2012.02.01110.1016/j.coph.2012.02.011 ↗
4. 10.1016/S0169-409X(02)00044-310.1016/S0169-409X(02)00044-3 ↗
5. 10.1016/j.addr.2012.09.03310.1016/j.addr.2012.09.033 ↗
6. 10.1016/j.addr.2015.10.01910.1016/j.addr.2015.10.019 ↗
7. 10.1016/j.biomaterials.2016.04.02710.1016/j.biomaterials.2016.04.027 ↗
8. 10.2165/00003495-199200444-0000310.2165/00003495-199200444-00003 ↗
9. 10.4065/84.6.53310.4065/84.6.533 ↗
10. 10.1089/hyb.1996.15.35110.1089/hyb.1996.15.351 ↗
11. 10.1056/NEJMra04318610.1056/NEJMra043186 ↗
12. 10.1053/j.seminoncol.2003.08.01310.1053/j.seminoncol.2003.08.013 ↗
13. 10.1634/theoncologist.2011-S1-0110.1634/theoncologist.2011-S1-01 ↗
14. 10.1200/JCO.2008.21.443710.1200/JCO.2008.21.4437 ↗
15. 10.1016/j.jconrel.2013.04.01010.1016/j.jconrel.2013.04.010 ↗
16. 10.1200/JCO.1991.9.2.30510.1200/JCO.1991.9.2.305 ↗
17. 10.1002/smll.20090062110.1002/smll.200900621 ↗
18. Expression of breast cancer resistance protein, lung resistance‐related protein, multidrug resistance‐associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response
19. 10.1038/srep2239010.1038/srep22390 ↗
20. 10.1016/j.jconrel.2016.03.00810.1016/j.jconrel.2016.03.008 ↗
21. 10.1155/2012/91537510.1155/2012/915375 ↗
22. 10.1016/j.colsurfb.2016.06.00210.1016/j.colsurfb.2016.06.002 ↗
23. 10.1007/s40204-015-0044-010.1007/s40204-015-0044-0 ↗
24. 10.1016/S1748-0132(07)70083-X10.1016/S1748-0132(07)70083-X ↗
25. 10.3390/ijms1709144010.3390/ijms17091440 ↗
26. 10.1007/s10856-015-5609-x10.1007/s10856-015-5609-x ↗
27. 10.2217/nnm.12.16910.2217/nnm.12.169 ↗
28. 10.1016/j.ces.2005.06.01910.1016/j.ces.2005.06.019 ↗
29. 10.1016/j.addr.2008.03.01210.1016/j.addr.2008.03.012 ↗
30. 10.1186/1556-276X-6-55510.1186/1556-276X-6-555 ↗
31. 10.1016/j.msec.2016.10.00810.1016/j.msec.2016.10.008 ↗
32. 10.1039/c3cs60149h10.1039/c3cs60149h ↗
33. 10.1016/j.colsurfb.2013.01.05110.1016/j.colsurfb.2013.01.051 ↗
34. 10.1039/C5BM00277J10.1039/C5BM00277J ↗
35. GaoY ChenY JiX HeX YinQ ZhangZ Shi J Li Y. Controlled intracellular release of doxorubicin in multidrug‐resistant cancer cells by tuning the shell‐pore sizes of mesoporous silica. ACS Nano2011;(12):9788–98.10.1021/nn2033105 ↗
36. 10.1021/acs.chemmater.6b0362910.1021/acs.chemmater.6b03629 ↗
37. 10.1002/smll.20090062110.1002/smll.200900621 ↗
38. 10.1021/nn100690m10.1021/nn100690m ↗
39. 10.4103/0975-7406.13096510.4103/0975-7406.130965 ↗
40. 10.1016/j.jconrel.2014.09.00110.1016/j.jconrel.2014.09.001 ↗
41. 10.1080/0265204080231257210.1080/02652040802312572 ↗
42. 10.1016/j.ijpharm.2016.11.03910.1016/j.ijpharm.2016.11.039 ↗
43. 10.1166/jnn.2014.908010.1166/jnn.2014.9080 ↗
44. 10.1021/nn404792510.1021/nn4047925 ↗
45. 10.1021/mp400469910.1021/mp4004699 ↗
46. 10.1517/17425247.3.1.13910.1517/17425247.3.1.139 ↗
47. 10.1016/j.jconrel.2017.01.01210.1016/j.jconrel.2017.01.012 ↗
48. The effect of process parameters on the size and morphology of poly(D,L‐lactide‐co‐glycolide) micro/nanoparticles prepared by an oil in oil emulsion/solvent evaporation technique10.1002/app.31595 ↗
49. 10.1002/pat.127910.1002/pat.1279 ↗
50. 10.1016/j.biomaterials.2011.07.03210.1016/j.biomaterials.2011.07.032 ↗
51. 10.1016/j.nano.2015.09.01410.1016/j.nano.2015.09.014 ↗
52. 10.1016/j.biomaterials.2017.01.00210.1016/j.biomaterials.2017.01.002 ↗
53. 10.1016/S1359-6446(03)02903-910.1016/S1359-6446(03)02903-9 ↗
54. 10.1016/j.polymer.2013.07.02210.1016/j.polymer.2013.07.022 ↗
55. 10.3389/fchem.2014.0004910.3389/fchem.2014.00049 ↗
56. 10.1016/j.nano.2013.07.00910.1016/j.nano.2013.07.009 ↗
57. 10.1016/j.biomaterials.2013.11.08610.1016/j.biomaterials.2013.11.086 ↗
58. 10.1021/nn505729m10.1021/nn505729m ↗
59. 10.1016/j.ijbiomac.2014.10.05210.1016/j.ijbiomac.2014.10.052 ↗
60. 10.1002/jbm.a.3448110.1002/jbm.a.34481 ↗
61. 10.1016/j.ijbiomac.2014.12.03710.1016/j.ijbiomac.2014.12.037 ↗
62. A novel injectable bio‐nanocomposite for bone tissue engineering applications
63. Chitosan and nanohydroxyapatite roles in physical and chemical characteristics of gelatin/chitosan/nanohydroxyapatite microspheres
64. 10.1016/j.carbpol.2009.06.02010.1016/j.carbpol.2009.06.020 ↗
65. 10.1016/j.carbpol.2017.03.03110.1016/j.carbpol.2017.03.031 ↗
66. Preparation and study of combinational drug delivery system based on chitosan nanoparticles for breast cancer treatment
67. 10.1016/j.biomaterials.2011.03.02210.1016/j.biomaterials.2011.03.022 ↗
68. 10.1002/mabi.20100033210.1002/mabi.201000332 ↗
69. 10.1016/j.biomaterials.2012.07.03110.1016/j.biomaterials.2012.07.031 ↗
70. 10.1039/c0jm01461c10.1039/c0jm01461c ↗
71. 10.1016/j.ymthe.2004.03.01510.1016/j.ymthe.2004.03.015 ↗
72. 10.1016/j.biomaterials.2014.02.00610.1016/j.biomaterials.2014.02.006 ↗
73. 10.1371/journal.pone.006003410.1371/journal.pone.0060034 ↗
74. 10.1016/j.jconrel.2014.11.01010.1016/j.jconrel.2014.11.010 ↗
75. 10.1016/j.jconrel.2012.08.02010.1016/j.jconrel.2012.08.020 ↗
76. 10.3109/1061186X.2013.81151110.3109/1061186X.2013.811511 ↗
77. 10.1016/j.biomaterials.2014.03.01210.1016/j.biomaterials.2014.03.012 ↗
78. 10.1016/j.ejpb.2010.06.01110.1016/j.ejpb.2010.06.011 ↗
79. 10.1016/j.actbio.2014.12.01810.1016/j.actbio.2014.12.018 ↗
80. 10.1038/nmat173710.1038/nmat1737 ↗
81. 10.1016/j.biomaterials.2014.04.02510.1016/j.biomaterials.2014.04.025 ↗
82. 10.1016/j.biomaterials.2012.10.05710.1016/j.biomaterials.2012.10.057 ↗
83. 10.1074/jbc.M110.12590610.1074/jbc.M110.125906 ↗
84. 10.1016/j.nano.2011.02.00110.1016/j.nano.2011.02.001 ↗
85. 10.1016/j.nano.2015.12.36010.1016/j.nano.2015.12.360 ↗
86. 10.1158/0008-5472.CAN-15-151810.1158/0008-5472.CAN-15-1518 ↗
87. 10.1016/j.jconrel.2007.05.03810.1016/j.jconrel.2007.05.038 ↗
88. 10.1016/j.jconrel.2009.04.02410.1016/j.jconrel.2009.04.024 ↗
89. 10.1016/j.nano.2010.12.00910.1016/j.nano.2010.12.009 ↗
90. 10.1016/j.nano.2011.05.00310.1016/j.nano.2011.05.003 ↗
91. 10.1016/j.biomaterials.2015.07.02710.1016/j.biomaterials.2015.07.027 ↗
92. 10.3390/ijms1502276110.3390/ijms15022761 ↗
93. 10.1021/nn507465d10.1021/nn507465d ↗
94. 10.1021/acs.molpharmaceut.5b0053610.1021/acs.molpharmaceut.5b00536 ↗
95. 10.1016/j.carbpol.2015.10.05010.1016/j.carbpol.2015.10.050 ↗
96. 10.1016/j.msec.2015.01.03310.1016/j.msec.2015.01.033 ↗